logo
Plus   Neg
Share
Email

Aquinox Pharmaceuticals Inc. (AQXP) Has Plunged To A New Low After Study Failed

Aquinox Pharmaceuticals Inc. (AQXP) announced Wednesday morning that its Phase 3 clinical trial of once-daily, oral rosiptor, for the treatment of interstitial cystitis/bladder pain syndrome, failed to meet its primary endpoint.

Aquinox Pharmaceuticals has gapped open dramatically lower this morning and is now down 12.73 at $2.58 on the highest volume of the year. The stock has plunged to a new low for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT